| Literature DB >> 34696566 |
Juwhan Choi1, Zepa Yang2, Jinhwan Lee3, Jun Hee Lee4, Hyun Koo Kim4, Hwan Seok Yong2, Sung Yong Lee1.
Abstract
PURPOSE: The usefulness of rehabilitation in patients with reduced lung function before lung surgery remains unclear, and there is no adequate method for evaluating the effect of rehabilitation. We aimed to evaluate the usefulness of rehabilitation in patients with non-small cell lung cancer (NSCLC) undergoing lung cancer surgery.Entities:
Keywords: Chronic obstructive pulmonary disease; Non-small-cell lung carcinoma; Pulmonary rehabilitation; Pulmonary surgical procedures
Mesh:
Year: 2021 PMID: 34696566 PMCID: PMC9296947 DOI: 10.4143/crt.2021.769
Source DB: PubMed Journal: Cancer Res Treat ISSN: 1598-2998 Impact factor: 5.036
Fig. 1HUESMcsa calculation. We drew the erector spinae muscles (first lumbar level) with a green line. For each computed tomography image, we calculated the muscle thresholds. The software program calculated the HUESMcsa (indicated in blue). (A) Muscle atrophy: HUESMcsa 975.8 cm2. (B) Muscle hypertrophy: HUESMcsa 5,910.1 cm2. HU, Hounsfield unit; HUESMcsa, Hounsfield unit of average intensity value of erector spinae muscle in cross-sectional area in computed tomography.
Fig. 2Flowchart of patient classification according to rehabilitation and propensity score matching.
Baseline characteristics in the rehabilitation and non-rehabilitation groups before and after propensity score matching
| Characteristic | Before matching | After matching | ||||||
|---|---|---|---|---|---|---|---|---|
|
|
| |||||||
| Rehabilitation group (n=75) | Non-rehabilitation group (n=250) | p-value | d | Rehabilitation group (n=45) | Non-rehabilitation group (n=45) | p-value | d | |
|
| 69.8±7.0 | 64.6±9.2 | < 0.001 | Infinity | 70.0±6.8 | 69.5±6.9 | 0.713 | 0.0730 |
|
| ||||||||
|
| ||||||||
|
| ||||||||
| Male | 59 (78.7) | 137 (54.8) | < 0.001 | Infinity | 30 (66.7) | 34 (75.6) | 0.352 | 0.2400 |
|
| ||||||||
| Female | 16 (21.3) | 113 (45.2) | 15 (33.3) | 11 (24.4) | ||||
|
| ||||||||
|
| 163.5±7.7 | 161.8±8.5 | 0.116 | 0.2042 | 162.7±8.3 | 163.3±7.7 | 0.709 | 0.0749 |
|
| ||||||||
|
| 64.8±10.2 | 63.0±8.5 | 0.203 | 0.2018 | 63.7±11.3 | 64.9±12.4 | 0.634 | 0.1012 |
|
| ||||||||
|
| ||||||||
|
| ||||||||
| Current smoker | 5 (6.7) | 23 (9.2) | 0.618 | 0.1294 | 4 (8.9) | 5 (11.1) | 0.621 | 0.2032 |
|
| ||||||||
| Ex-smoker | 23 (30.7) | 85 (34.0) | 17 (37.8) | 21 (46.7) | ||||
|
| ||||||||
| Non-smoker | 47 (62.7) | 142 (56.8) | 24 (53.3) | 19 (42.2) | ||||
|
| ||||||||
|
| ||||||||
|
| ||||||||
| COPD | 19 (25.3) | 71 (28.4) | 0.603 | 0.0861 | 17 (37.8) | 21 (46.7) | 0.393 | 0.2015 |
|
| ||||||||
| Asthma | 1 (1.3) | 8 (3.2) | 0.690 | 0.4932 | 1 (2.2) | 2 (4.4) | > 0.99 | 0.3948 |
|
| ||||||||
| IPF | 1 (1.3) | 6 (2.4) | > 0.99 | 0.3301 | 1 (2.2) | 2 (4.4) | > 0.99 | 0.3948 |
|
| ||||||||
| Hypertension | 39 (52.0) | 129 (51.6) | 0.952 | 0.0088 | 26 (57.8) | 25 (55.6) | 0.832 | 0.0499 |
|
| ||||||||
| Diabetes | 17 (22.7) | 59 (23.6) | 0.867 | 0.0289 | 10 (22.2) | 8 (17.8) | 0.598 | 0.1537 |
|
| ||||||||
| Coronary artery disease | 13 (17.3) | 38 (15.2) | 0.656 | 0.0865 | 8 (17.8) | 13 (28.9) | 0.213 | 0.3477 |
|
| ||||||||
| Cerebrovascular accident | 4 (5.3) | 21 (8.4) | 0.382 | 0.2686 | 5 (11.1) | 5 (11.1) | > 0.99 | 0.0000 |
|
| ||||||||
|
| ||||||||
|
| ||||||||
| LAMA | 1 (1.3) | 2 (0.8) | < 0.001 | 0.5769 | 1 (2.2) | 0 | 0.795 | 0.0343 |
|
| ||||||||
| LABA+LAMA | 19 (25.3) | 25 (10.0) | 10 (22.2) | 9 (20.0) | ||||
|
| ||||||||
| ICS+LABA | 6 (8.0) | 5 (2.0) | 2 (4.4) | 4 (8.9) | ||||
|
| ||||||||
| Triple therapy | 2 (2.7) | 1 (0.4) | 0 | 1 (2.2) | ||||
|
| ||||||||
| None | 47 (62.7) | 217 (86.8) | 32 (71.1) | 31 (68.9) | ||||
|
| ||||||||
|
| ||||||||
|
| ||||||||
| Neoadjuvant chemotherapy | 5 (6.7) | 12 (4.8) | 0.556 | 0.1920 | 3 (6.7) | 4 (8.9) | > 0.99 | 0.1719 |
|
| ||||||||
| Neoadjuvant concurrent chemoradiotherapy | 7 (9.3) | 6 (2.4) | 0.014 | 0.7894 | 2 (4.4) | 2 (4.4) | > 0.99 | 0.0000 |
|
| ||||||||
|
| ||||||||
|
| ||||||||
| Lobectomy | 39 (52.0) | 177 (70.8) | 0.006 | 0.3175 | 30 (66.7) | 31 (68.9) | > 0.99 | 0.0000 |
|
| ||||||||
| Segmentectomy | 13 (17.3) | 33 (13.2) | 5 (11.1) | 5 (11.1) | ||||
|
| ||||||||
| Wedge resection | 4 (5.3) | 5 (2.0) | 1 (2.2) | 0 | ||||
|
| ||||||||
| Bilobectomy | 5 (6.7) | 3 (1.2) | 3 (6.7) | 2 (4.4) | ||||
|
| ||||||||
| Lobectomy and segmentectomy | 4 (5.3) | 5 (2.0) | 1 (2.2) | 1 (2.2) | ||||
|
| ||||||||
| Lobectomy and wedge resection | 10 (13.3) | 27 (10.8) | 5 (11.1) | 6 (13.3) | ||||
|
| ||||||||
|
| ||||||||
|
| ||||||||
| Right upper lobe | 16 (21.3) | 62 (24.8) | 0.154 | 0.2261 | 12 (26.7) | 8 (17.8) | 0.882 | 0.1138 |
|
| ||||||||
| Right middle lobe | 1 (1.3) | 15 (6.0) | 1 (2.2) | 1 (2.2) | ||||
|
| ||||||||
| Right lower lobe | 15 (20.0) | 43 (17.2) | 7 (15.6) | 11 (24.4) | ||||
|
| ||||||||
| Left upper lobe | 14 (18.7) | 61 (24.4) | 10 (22.2) | 9 (20.0) | ||||
|
| ||||||||
| Left lower lobe | 10 (13.3) | 34 (13.6) | 6 (13.3) | 7 (15.6) | ||||
|
| ||||||||
| Two or more lobes | 19 (25.3) | 35 (14.0) | 9 (20.0) | 9 (20.0) | ||||
Values are presented as mean±SD or number (%). COPD, chronic obstructive pulmonary disease; d, standardized mean difference; ICS, inhaled corticosteroids; IPF, idiopathic pulmonary fibrosis; LABA, long acting B agonist bronchodilator; LAMA, long acting antimuscarinic agent bronchodilator; SD, standard deviation.
Preoperative pulmonary function test data before and after propensity score matching
| Pulmonary function test parameter (before surgery) | Before matching | After matching | ||||||
|---|---|---|---|---|---|---|---|---|
|
|
| |||||||
| Rehabilitation group (n=75) | Non-rehabilitation group (n=250) | p-value | d | Rehabilitation group (n=45) | Non-rehabilitation group (n=45) | p-value | d | |
| ΔFEV1 (L) | 2.2±0.6 | 2.5±0.6 | < 0.001 | Infinity | 2.3±0.6 | 2.4±0.5 | 0.310 | 0.1811 |
|
| ||||||||
| ΔFEV1 (%) | 78.9±15.0 | 91.7±13.6 | < 0.001 | Infinity | 83.9±14.6 | 86.3±13.5 | 0.431 | 0.1707 |
|
| ||||||||
| ΔFVC (L) | 3.4±0.9 | 3.5±0.8 | 0.334 | 0.1214 | 3.4±0.9 | 3.5±0.8 | 0.322 | 0.1174 |
|
| ||||||||
| ΔFVC (%) | 85.4±14.4 | 93.3±11.8 | < 0.001 | Infinity | 88.0±14.6 | 90.6±11.4 | 0.350 | 0.1985 |
|
| ||||||||
| FEV1/FVC | 65.6±10.9 | 73.2±8.7 | < 0.001 | Infinity | 68.1±9.7 | 67.8±8.4 | 0.853 | 0.0331 |
|
| ||||||||
| DLCO (L) | 14.3±3.3 | 16.9±3.9 | < 0.001 | Infinity | 14.8±3.1 | 15.6±3.9 | 0.290 | 0.2271 |
|
| ||||||||
| DLCO (%) | 75.7±14.8 | 87.3±14.9 | < 0.001 | Infinity | 79.8±13.6 | 81.9±15.3 | 0.482 | 0.1451 |
|
| ||||||||
| DLCO/VA (L) | 3.2±0.8 | 3.7±0.7 | < 0.001 | Infinity | 3.4±0.8 | 3.3±0.7 | 0.728 | 0.1330 |
|
| ||||||||
| DLCO/VA (%) | 85.2±18.1 | 93.4±15.8 | < 0.001 | Infinity | 88.4±18.0 | 87.3±16.9 | 0.773 | 0.0630 |
Values are presented as mean±SD. d, standardized mean difference; DLCO, carbon monoxide diffusing capacity; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; VA, alveolar volume.
Differences in postoperative lung function before and after propensity score matching
| Pulmonary function test parameter | Before matching | After matching | ||||
|---|---|---|---|---|---|---|
|
|
| |||||
| Rehabilitation group (n=75) | Non-rehabilitation group (n=250) | p-value | Rehabilitation group (n=45) | Non-rehabilitation group (n=45) | p-value | |
| ΔFEV1 (L) | −0.3±0.3 | −0.5±0.3 | < 0.001 | −0.3±0.3 | −0.5±0.3 | 0.001 |
|
| ||||||
| ΔFEV1 (%) | −10.5±9.0 | −19.0±10.9 | < 0.001 | −11.6±9.3 | −18.8±11.0 | 0.001 |
|
| ||||||
| ΔFVC (L) | −0.5±0.4 | −0.7±0.5 | 0.006 | −0.6±0.4 | −0.8±0.5 | 0.019 |
|
| ||||||
| ΔFVC (%) | −13.8±9.5 | −18.9±11.3 | < 0.001 | −14.4±9.8 | −20.7±12.7 | 0.010 |
|
| ||||||
| ΔDLCO (L) | −1.9±2.4 | −2.7±2.6 | 0.021 | −1.9±2.4 | −2.4±3.3 | 0.385 |
|
| ||||||
| ΔDLCO (%) | −10.2±12.0 | −14.0±13.3 | 0.029 | −10.4±12.0 | −13.2±16.1 | 0.364 |
|
| ||||||
| ΔDLCO/VA (L) | 0.0±0.5 | 0.1±0.5 | 0.572 | 0.0±0.4 | 0.2±0.6 | 0.193 |
|
| ||||||
| ΔDLCO/VA (%) | 1.0±11.9 | 1.8±12.7 | 0.617 | 1.0±9.9 | 4.3±14.6 | 0.210 |
Values are presented as mean±SD. Δ, differences before and after surgery; DLCO, carbon monoxide diffusing capacity; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; VA, alveolar volume.
Fig. 3Correlation analysis of pulmonary function test parameters and the HUESMcsa: Forced expiratory volume in 1 second (FEV1) (A) and forced vital capacity (FVC) (B). HU, Hounsfieldunit; HUESMcsa, Hounsfieldunit of average intensity value of erector spinae muscle in cross-sectional area in computed tomography.
HUESMcsa measurement using computed tomography images
| Before matching | After matching | |||||
|---|---|---|---|---|---|---|
|
|
| |||||
| Rehabilitation group (n=75) | Non-rehabilitation group (n=250) | p-value | Rehabilitation group (n=45) | Non-rehabilitation group (n=45) | p-value | |
| Before surgery (cm2) | 3,717.6±823.0 | 3,712.3±970.0 | 0.966 | 3,580.4±829.0 | 3,787.9±1271.9 | 0.362 |
|
| ||||||
| Δ HUESMcsa | −15.6±166.5 | −159.6±199.0 | < 0.001 | −22.6±152.8 | −136.4±172.7 | 0.001 |
|
| ||||||
| Δ HUESMcsa (%) | −0.4±4.6 | −4.0±5.2 | < 0.001 | −0.6±4.4 | −3.4±4.1 | 0.003 |
Values are presented as mean±standard deviation. Δ, differences before and after surgery; HU, Hounsfield unit; HUESMcsa, Hounsfield unit of average intensity value of erector spinae muscle in cross-sectional area in computed tomography.
HUESMcsa (%)=Postoperation HUESMcsa–Preoperation HUESMcsa/Preoperation HUESMcsa×100.
Clinical outcomes related to surgery
| Before matching | After matching | |||||
|---|---|---|---|---|---|---|
|
|
| |||||
| Rehabilitation group (n=75) | Non-rehabilitation group (n=250) | p-value | Rehabilitation group (n=45) | Non-rehabilitation group (n=45) | p-value | |
| Period from admission to discharge (day) | 10.1±6.0 | 8.4±4.3 | 0.029 | 9.3±6.2 | 9.4±5.0 | 0.926 |
|
| ||||||
| HFNC application | 68 (90.7) | 219 (87.6) | 0.469 | 41 (91.1) | 35 (77.8) | 0.081 |
|
| ||||||
| Duration of HFNC use | 3.2±1.8 | 2.9±1.6 | 0.171 | 3.4±2.0 | 3.4±1.8 | 0.982 |
|
| ||||||
| 90-Day mortality | 0 | 1 (0.4) | > 0.99 | 0 | 0 | > 0.99 |
|
| ||||||
| 180-Day mortality | 2 (2.7) | 3 (1.2) | 0.326 | 2 (4.4) | 1 (2.2) | > 0.99 |
Values are presented as mean±SD or number (%). HFNC, high-flow nasal cannula.
Major postoperative complications (occurrence within 1 month)
| Before matching | After matching | |||||
|---|---|---|---|---|---|---|
|
|
| |||||
| Rehabilitation group (n=75) | Non-rehabilitation group (n=250) | p-value | Rehabilitation group (n=45) | Non-rehabilitation group (n=45) | p-value | |
|
| 10 (13.3) | 50 (20.0) | 0.192 | 4 (8.9) | 12 (26.7) | 0.027 |
|
| ||||||
| When two or more different events occur | 0 | 2 (0.8) | > 0.99 | 0 | 0 | > 0.99 |
|
| ||||||
| Major cardiovascular events or arrhythmia | 0 | 5 (2.0) | 0.593 | 0 | 1 (2.2) | > 0.99 |
|
| ||||||
| Pneumonia | 3 (4.0) | 6 (2.4) | 0.436 | 0 | 1 (2.2) | > 0.99 |
|
| ||||||
| Pneumothorax | 3 (4.0) | 9 (3.6) | > 0.99 | 1 (2.2) | 1 (2.2) | > 0.99 |
|
| ||||||
| Chest pain or dyspnea | 1 (1.3) | 8 (3.2) | 0.690 | 1 (2.2) | 0 | > 0.99 |
|
| ||||||
| Pulmonary embolism or deep vein thrombosis | 3 (4.0) | 19 (7.6) | 0.276 | 2 (4.4) | 8 (17.8) | 0.044 |
|
| ||||||
| Pleural effusion | 0 | 2 (0.8) | > 0.99 | 0 | 0 | > 0.99 |
|
| ||||||
| Etc. | 0 | 3 (1.2) | > 0.99 | 0 | 1 (2.2) | > 0.99 |
Values are presented as number (%).
All cases where ‘hospitalization’ or ‘visit the emergency room’ or ‘intervention (procedure or anticoagulation) was added’ within one month for the reasons listed in the table,
Etc. contains dizziness or general weakness.